BackNeuroSense Therapeutics Overview

NeuroSense Therapeutics Receivables

Latest receivables for NRSN: $33K.

Get informed when a big investor buys or sells

+ Follow
Receivables
$33000.00
↓ 79.88% YoYΔ $-131000.00 vs prior year quarter

Peer average

Loading

NeuroSense Therapeutics Receivables History

Loading

NeuroSense Therapeutics vs. peers: Receivables Comparison

Loading

NeuroSense Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

NeuroSense Therapeutics (NRSN) FAQ

As of the most recent data (December 2025), NRSN shows a receivables of $33K. That compares with $160K in the prior-year period — down 79.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NRSN's receivables is now $33K (was $160K) — a 79.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether NeuroSense Therapeutics is outperforming or lagging.

Tracking NRSN's receivables over time shows whether NeuroSense Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $33K That compares with $160K in the prior-year period — down 79.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has NeuroSense Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $33K) with ownership activity and broader fundamentals.